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Abstract
Injectable contraceptives are fast becoming the method of choice among married 
women in sub-Saharan Africa. In several countries in the region, the proportion of 
women using injectable methods has surpassed the proportion of women using 
the pill. This is true even in some countries where the pill had been the most pop-
ular modern method in the 1980s and 1990s. This paper analyzes data from six 
sub-Saharan African countries that have participated four or more times in the 
Demographic and Health Surveys program to investigate recent increases in prev-
alence of injectable contraceptives and identify factors that drive the increase. It 
discusses the programmatic implications of this trend for the region, especially in 
terms of contraceptive security and sustainability. 
Introduction
Although sub-Saharan Africa still has the 
lowest level of contraceptive preva-
lence among all the major regions of the 
world (United Nations, 2011), over the 
past two decades, the proportion of 
married women using modern contra-
ceptive methods has increased in 
almost every country in the region. 
One of the most noticeable things that 
have accompanied the rising contracep-
tive prevalence in many countries in the 
region is the change in the method mix. 
Initially, the pill was the main modern 
method of contraception in most coun-
tries in the region. However, in recent 
years, the use of injectable contracep-
tives has increased and the rate of 
increase has been so fast in many coun-
tries that they have become the leading 
method (Lande and Richey, 2006:3). 
According to a recent estimate by the 
United Nations (2011), the proportion 
of married women in sub-Saharan 
Africa who used injectables in 2009 
(6.8%) was about double the global 
average (3.5%). 
This rapid rate of increase in the 
use of injectable contraceptives is an 
exciting programmatic success story 
because an increasing proportion of 
African women are finally using a con-
traceptive method that is highly effec-
tive, reversible, convenient to use, and 
relatively long-lasting (Sullivan et al., 
2006, Glasier and Shields, 2006:1). 
Moreover, these long-lasting injecta-
bles have extremely low failure rates – 
3% in typical use and 0.3% if used as 
recommended (Trussell, 2004). And 
since user-failure is one major reason 
why so many women who use coitus-
dependent methods and methods 
requiring daily dosage end up with unin-
tended pregnancies, a rapid increase in 
a method such as injectables will trans-
late to a decline in the proportion of 
pregnancies that is unintended (Chris-
man et al., 2006:125). On the other 
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hand, this rapid increase in the use of 
injectables often raises such issues as 
commodity security, cost, sustainability, 
and the increasing skewness or lopsid-
edness in contraceptive method mix. 
Injectable contraceptives (or inject-
ables) are given to users by means of 
intramuscular injection in the upper 
arm or buttock, and they work by pre-
venting ovulation and by thickening the 
cervical mucus, making it a barrier to 
sperm. As commonly used, the failure 
rates of injectables are less than 1%, 
compared to 6-8% in pill, 14% for 
male condoms and 20% for diaphragm 
(Hatcher et al., 1997, CDC, 1999, Trus-
sell, 2004). There are varieties of inject-
able contraceptives, and they are 
usually classified according to the dura-
tion of their efficacy: three months, two 
months, and monthly. The most widely 
used injectable contraceptives in sub-
Saharan Africa, and hence the one this 
paper focuses on, is the long-acting 
depot medroxyprogesterone acetate 
(DMPA) or Depo Provera. One vial of 
DMPA (150 mg) protects against con-
ception for three months, with two 
weeks of grace allowed in cases where 
users are unable to have their shots 
within three months. An example of 
two-monthly injectable contraceptives 
is Norethindrone enanthate (NET EN), 
which is called Noristerat. This is a pro-
gestin-only (or progestogen-only) injec-
table contraceptive. The third type of 
injectables is the combined progestin 
and estrogen, which are given monthly. 
They include Cyclofem and Mesigyna 
(Lande and Richey, 2006).
Various studies exist in the litera-
ture on injectable contraceptives. A 
large proportion of these studies focus 
on their side effects and some focus on 
their acceptability and discontinuation 
rates. Although some of the studies on 
side effects and discontinuation have 
found high discontinuation rates among 
users of injectables, such studies tend 
to be outside of sub-Saharan Africa. For 
example, a study of Turkish women 
found 71% discontinuation rates 
(Aktun et al., 2005). A study in Egypt 
found a 12 months discontinuation rate 
of 70% for injectables (Tolley et al, 
2005). Studies in sub-Saharan Africa 
tend to find lower discontinuation rates 
for injectables. For example, Ruminjo et 
al. (2005) report a 12 months discontin-
uation rate of only 25% for Depo 
Provera. In Ghana, Parr (2003) found 
that users of injectables tend to use 
them for relatively long periods. A simi-
lar finding was reported by Mitchel and 
Thistle (2004) in rural Zimbabwe. 
Scholars have also noted the rising 
importance of injectables in the contra-
ceptive method mix of several sub-
Saharan African countries. An example 
is the work of Magadi and Curtis (2003) 
in Kenya. Surprisingly, the literature on 
a systematic analysis of the patterns, 
trends and determinants of injectables 
in sub-Saharan Africa is sparse. 
Various studies have also focused 
on the side effects of injectables. One 
of them is possible loss of bone mineral 
density (BMD) among those who use 
the method for longer than two years. 
Some studies have found that the effect 
on bone loss is negligible and reversible 
(Petitti et al., 2000), some found major 
effects only among adolescents (see 
Gold and Bachrach, 2004), while some 
others found the effect on bone mineral 
density occurs across all age groups 
(see Cromer, 1999). To resolve this lack 
of consistency in findings, the World 
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Health Organization (WHO) convened 
a consultative meeting in Geneva in 
2005 to review the evidence. The con-
clusion from that meeting was that 
DMPA use reduces BMD in women 
who have attained peak bone mass, but 
when DMPA use is discontinued, BMD 
returns over a period of 2-3 years to a 
level that is comparable to that among 
non-users. Therefore, WHO recom-
mends that there should be no restric-
tion on the use of DMPA by women 
between the ages of 18 and 45 who are 
otherwise eligible to use DMPA.
Thus, the prevalence of injectable 
contraceptive continues to increase in 
several countries in sub-Saharan Africa. 
One of the key questions of interest in 
this paper is: what are the drivers of the 
increasing popularity of the injectables 
in the region? In the section that fol-
lows, we piece together some of the 
explanation that we could garner from 
the literature and that are relevant to 
explaining the rising prevalence of 
injectable contraceptives in sub-Saharan 
Africa.
Why is the use of injectable 
contraceptives increasing?
Several levels of explanation could be 
offered for the rising popularity of 
injectables in sub-Saharan Africa. They 
include method-specific advantages that 
injectables offer; its cultural relevance 
and convenience, and the issue of 
secrecy or privacy. For example, in 
terms of method-specific factors, 
injectables are highly effective, long-
lasting and easily reversible. One dose 
of DMPA prevents pregnancies for 
months, which means fewer visits to 
clinics and freedom from daily dose of 
pills. Some women consider the 
absence of the monthly period that 
accompanies the use of injectables as a 
major advantage of the method (Lande 
and Richey, 2006). Injectables could also 
be used by breastfeeding mothers and 
may be appealing to women who are 
uncomfortable with the estrogen side 
effects of pills. There is evidence that 
use of DMPA is associated with signifi-
cant weight gains in some women (Ber-
enson and Rahman, 2009), but we do 
not know whether or not this side 
effect might make the method attrac-
tive, especially in settings where food 
insecurity is frequent and where 
weight-gains are seen as evidence of 
good living. 
Moreover, there are other advan-
tages that are very specific to some 
injectable contraceptives, although they 
may not be known to individual users 
unless providers use the information 
during counseling. For example, injecta-
bles have been found to have some 
non-contraceptive benefits, such as 
reduced risks of ectopic pregnancies, 
symptomatic pelvic inflammatory dis-
ease, and uterine fibroids. They 
increase iron levels in the blood and 
they are associated with a reduced risk 
of sickle cell anemia crises, and less 
painful crises when crises occur (Lande 
and Richey, 2006). There is evidence 
that the use of some injectable contra-
ceptives is associated with a reduction 
in the risk of endometrial cancer (Kar-
mitz, 2001), and it has been observed 
that women with epilepsy who use 
Depo Provera may experience less fre-
quent seizures. 
In some African countries, prefer-
ence for injection over pills has been 
observed (Lohiniva et al., 2005, Ade-
tunji, 1996, Hodes, 1997). The extent 
to which this plays a role in the rising 
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prevalence of injectable contraceptives 
is unknown. For example, because of 
the belief in injection, Lohiniva and col-
leagues found that almost 20% of all 
prescriptions in their Egypt study 
included an injection. It has been 
reported that the popularity of child 
immunization in a Nigerian community 
had something to do with its translation 
as a preventive injection, which syn-
chronizes with the traditional principle 
of using something to defend against an 
anticipated but unwanted disease or 
attack, with the aim of minimizing or 
eliminating its negative effects (Ade-
tunji, 1996). If this same idea is carried 
over into the use of contraceptive injec-
tion, it may be that injectables are con-
sidered a ‘vaccination’ against unwanted 
pregnancies in the face of exposure to 
its risks. Hodes (1997) also noted that 
there is a preference among Ethiopians 
for injection over pills whenever such 
an option was available. Available evi-
dence from Demographic and Health 
Surveys (DHS) shows a rapid increase 
in the use of injectable contraceptives in 
Ethiopia. However, the extent to which 
African preference for injections is 
widespread is unknown, and it does not 
explain why injectable contraceptives 
are not that popular in some African 
countries. 
Beyond cultural preference for 
injections, there is another set of expla-
nations that revolves around conven-
ience: the notion that women who do 
not want the constraining regimen of a 
pill-a-day would find injectables, partic-
ularly DMPA, very convenient. DMPA 
combines high long-lasting effectiveness 
with reversibility and privacy of use; the 
injection can be obtained quickly in clin-
ics, and it leaves no traces behind in the 
house to be discovered by others. 
Hence, no-one can tell that a contra-
ceptive is being used. The latter point 
has much to do with the secrecy 
hypothesis that some scholars have 
alluded to as a reason for the rapid 
increase in the adoption of the method 
(Phillips et al., 1997, Biddlecom and 
Fapohunda, 1998).
The secret–use hypothesis posits 
that many women who use injectables 
do so because they are able to hide 
their contraceptive practices from their 
spouses, and perhaps from other family 
members who may frown on their use 
of contraception. Anecdotes abound 
about African women who come to 
market with their wares, but stop by 
clinics, bare their arms, receive their 
contraceptive injections and go home. 
There are stories about women who 
bring their children for immunization or 
check-up and take their contraceptive 
injections before going home. Studies 
are confirming the importance of this 
secrecy factor in Africa (Phillips et al., 
1997, Biddlecom and Fapohunda, 1998, 
Phillips and Bawah, 2005). The Nav-
rongo project found that a high propor-
tion (92%) of contraceptive users were 
interested in DMPA mainly because it 
could be used secretly (Phillips and 
Bawah, 2005:3). Many DMPA users in 
Navrongo did not want their partners 
to know that they were using any con-
traceptive method. Thus, most women 
in the area who were not using injecta-
bles opted for NORPLANTS, rather 
than oral pills. So great was the fear of 
their contraceptive practice being 
exposed that about 42% of women 
known to the project as users of con-
traceptives reported non-use of contra-
ceptives when asked in surveys. 
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Biddlecom and Fapohunda (1998) in 
their Zambia study reported that 6-
20% of women used contraceptives 
secretly. Thus, secrecy and privacy 
could be very important to women 
whose spouses do not support contra-
ceptive use, or where there are spousal 
disagreements over the number and 
timing of pregnancies. The secrecy 
hypothesis has also been offered as one 
of the reasons for the cultural accepta-
bility of Depo Provera in many societies 
(CDC, 1999:350). 
In summary, there are method-spe-
cific advantages that injectable contra-
ceptives offer its users. There are also 
cultural relevance, the convenience 
appeals, and the elements of secrecy. It 
is likely that the reasons why women 
choose them would vary from individ-
ual to individual, and from setting to 
setting. Whatever the reason for use, 
there is some evidence in various DHS 
reports that the prevalence of injecta-
bles is increasing even in rural areas of 
sub-Saharan Africa. A study in rural 
Zimbabwe reported high satisfaction 
among users of DMPA and reported 
that the method was mainly used for 
birth spacing (Mitchel and Thistle, 
2004). If the method is used mainly by 
women who want to delay or space 
births, reversibility will be an advantage, 
but it may also translate to high discon-
tinuation rates for injectables, although 
method discontinuation rates are not 
addressed in this paper. 
Data and methods
Data from six sub-Saharan African 
countries that have participated three 
or more times in the Demographic and 
Health Surveys (DHS) program at the 
time this analysis started in 2006, 
whose standard-recode data files were 
available for download, and where at 
least 15% of currently married women 
were using a modern contraceptive 
method were selected. We set a mod-
ern contraceptive prevalence rate of 
15% to ensure that we have sufficient 
number of cases for the analysis. The 
countries that met these criteria are 
Ghana, Kenya, Madagascar, Malawi, 
Tanzania and Zimbabwe. The most 
recent datasets at the time this analysis 
began are 2003 Ghana DHS, 2003 Ken-
ya DHS, 2003/4 Madagascar DHS, 2004 
Malawi DHS, 2004 Tanzania DHS and 
2005 Zimbabwe DHS. Although Tables 
1 and 2 have now been updated with 
information from the latest DHS in 
these countries, the multivariate analy-
ses are based on the latest surveys at 
the beginning of the analysis. This is 
especially necessary because husbands’ 
attitude to family planning, one of the 
key determinants in our multivariate 
analysis, is missing from the latest DHS 
datasets.
Since this paper focuses on trends 
in the use of injectable methods, the 
first task is to illustrate the rise or oth-
erwise in their popularity in sub-Saha-
ran Africa. We did this by presenting 
trends in DMPA relative to other major 
methods in the contraceptive method 
mix in a selected number of countries. 
We calculated the percentage of users 
of modern contraceptives who are 
using injectables or the pill, and their 
trends in each country. We also investi-
gated some of the socio-demographic 
determinants of the use of injectables 
using multivariate logistic regression 
technique. The variables included in the 
models are women’s level of education, 
rural-urban residence, husband’s atti-
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tude to family planning, current age, 
and number of living children. The 
models were limited to women who 
are currently married or in unions since 
the most common indicator of contra-
ceptive prevalence is its use among 
these women. Therefore, marital status 
was not included as a variable. In the 
logistic regression models, women 
using injectable contraceptives in our 
sample were coded 1, non-users of 
injectables were coded zero. 
As noted earlier in the paper, one 
set of explanations revolves around 
what could be termed the convenience 
hypothesis: the notion that injectables 
are long-acting methods and hence 
require less frequent visits to providers; 
and that they offer freedom from daily 
regimen of pills and are not coitus-
dependent. They are also offered as 
injections in settings where women go 
for other services and by trained pro-
fessionals. These are conveniences that 
may make the method very appealing 
to women with low levels of education 
and those in rural areas. Therefore, the 
prevalence of injectables use was pre-
sented by rural urban residence and the 
trend over time is assessed to see if the 
use of injectables increased faster in 
rural areas and among women with low 
education. We expected injectables to 
rise fast in rural areas where attitudes 
to family limitation may be negative, 
where husband-wife communication 
about family planning may be uncom-
mon, where men’s family size ideals 
may be higher than the woman’s, and 
where gossip and other forms of dif-
fused sanction may make privacy highly 
desirable to users of contraceptives 
(Ntozi and Kabera, 1991). 
This brings us to the secret use 
hypothesis which has dotted the litera-
ture in one form or another (Rutenberg 
and Watkins, 1996, Phillips et al., 1997, 
Biddlecom and Fapohunda, 1998). We 
tested this hypothesis by using data 
from DHS couple data files that are 
available from the countries. 
Findings
A. Levels and Trends 
Table 1 shows the levels and trends in 
the use of major modern contraceptive 
methods. The results indicate an 
increasing prevalence of modern meth-
ods in general, and a particularly rapid 
increase in the use of injectables. For 
example, in Malawi, between 1992 and 
2010, the prevalence of modern meth-
ods among married women increased 
sixfold (from 7 to 42%), However, the 
prevalence of injectable contraceptives 
increased about seventeenfold – rising 
from a low of 1.5% to 26%. 
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Table 1 The percentage of married women using selected contraceptive methods in six 
sub-Saharan African countries
Any 
Modern
Pill Injectable Condom IUD Fem. 
Sterilzn 
Ghana
       1988 4.2 1.8 0.3 0.3 0.5 1.0
       1993 10.1 3.2 1.6 2.2 0.9 0.9
       1998 13.3 3.9 3.1 2.7 0.7 1.3
       2003 18.7 5.5 5.4 3.1 0.9 1.9
       2008 16.6 4.7 6.2 2.4 0.2 1.6
Kenya
       1989 17.9 5.2 3.3 0.5 3.7 4.7
       1993 27.3 9.5 7.2 0.8 4.2 5.5
       1998 31.5 8.5 11.8 1.3 2.7 6.2
       2003 31.5 7.5 14.3 1.2 2.4 4.3
       2008/9 39.4 7.2 21.6 1.8 1.6 4.8
Madagascar
       1992 5.1 1.4 1.6 0.5 0.5 0.9
       1997 9.7 2.4 4.7 0.7 0.5 1.0
       2003/4 18.3 3.4 10.2 1.0 0.6 1.1
       2008/9 29.2 6.0 17.9 1.1 0.4 1.1
Malawi
       1992 7.4 2.2 1.5 1.6 0.3 1.7
        2000 26.1 2.7 16.4 1.6 0.1 4.7
        2004 28.1 2.0 18.0 1.8 0.1 5.8
        2010 42.2 2.5 25.8 2.5 0.3 9.7
Tanzania
        1992         6.6 3.4 0.4 0.7 0.4 1.6
        1996 13.3 5.5 4.5 0.8 0.6 1.9
        1999 16.9 5.3 6.3 2.7 0.4 2.0
        2004 20.0 5.9 8.3 2.0 0.2 2.6
        2010 27.4 6.7 10.6 2.3 0.6 3.5
Zimbabwe
        1988 36.1 31.0 0.3 1.2 1.1 2.3
        1994 42.2 33.1 3.2 2.3 1.0 2.3
        1999 50.4 35.5 8.1 1.8 0.9 2.6
        2005/6 58.4 43.0 9.9 1.4 0.3 2.0
Source: Analysis of DHS data from STATcompiler
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In Kenya, the percentage of women 
using injectables increased from 3.3% 
in 1989 to 21.6% in 2008 – a sevenfold 
increase – while the percentage of 
women using the pills increased from 
5.2% to 7.5% over the same period. 
Even between 1998 and 2003 when 
overall modern CPR stagnated in 
Kenya, the prevalence of injectables still 
increased by 21%. In 1989, the per-
centage of women using the pills was 
57% higher than the percentage using 
injectables, but by 2008, the proportion 
of women using injectables was triple 
the percentage using the pills. In Mada-
gascar, the percentage of married 
women using injectables increased from 
1.6% in 1992 to 17.9% in 2008/9 – an 
elevenfold increase.
In Tanzania, while modern CPR 
increased from 6% to about 27.4% 
between 1992 and 2010 and the preva-
lence of pills doubled (from 3.4% to 
6.7%), the prevalence of injectables 
increased steeply from a low of 0.4% 
to about 10.6%. In Ghana, although the 
pill was the leading modern method 
used between 1988 and 1998, by 2008, 
the prevalence of injectables had sur-
passed that of pills. Zimbabwe is one of 
the few countries in the region where 
the pill continues to be the dominant 
method of contraception among mar-
ried women. Between 1988 and 2005/
6, the percentage of married women 
using the pills increased from 36% to 
58%. Even then, pill users as a percent-
age of women using modern contracep-
tives decreased from 86% in 1988 to 
74% in 2005/6. Within the same 
period, the percentage using the inject-
able method rose dramatically from less 
than 1% to about 10%. However, 
although the percentage using injecta-
bles is still small in comparison with 
those using the pill, its relative size in 
the method mix has increased from less 
than 1% in 1988 to 17% in 2005/6. 
In Table 2, the relative contributions 
of pills and injectables to the modern 
method mix are presented. The results 
show a general rapid increase in the 
percentage of injectable users in the 
modern method mix and a relative 
decrease in the percentage of pill users. 
For example in Ghana, only 7% of mar-
ried women who were using modern 
contraceptive methods reported inject-
ables in 1988. By 2008, the percentage 
reporting injectables had increased to 
37%. However, whereas 43% of mar-
ried women who were using modern 
contraceptives in Ghana in 1988 relied 
on the pills, by 2008, that percentage 
had declined to 28%. Similarly, in 
Malawi, only 20% of married women 
using modern contraceptives reported 
injectables as their current method in 
1992, but by 2010, that percentage had 
increased to 61%. Within the same 
period, the percentage of modern con-
traceptive users reporting the use of 
the pill declined from 30% to 6%. 
In Kenya, between 1989 and 2008/
09, the percentage of injectables users 
among married women using modern 
contraceptive methods increased from 
18% to 55%, whereas the percentage 
that depended on pills decreased from 
29% to 18% (Table 2). In Madagascar, 
31% of modern contraceptive users 
reported the use of injectables, but by 
2003/4, that percentage had increased 
to 56%. In Tanzania, only 6% of mod-
ern method users were using injecta-
bles in 1992. By 2010, that percentage 
had increased to 39% while the per-
centage of contraceptive users that 
used pills decreased from 52% to 25%. 
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Table 2 Percentage of women currently using a modern contraceptive method who 
reported the use of pills or injectables
CPR (All modern 
methods)
Pill users as % of 
modern CPR
Injectable users as 
% of modern CPR
Ghana
       1988 100 42.9 7.1
       1993 100 31.7 15.8
       1998 100 29.3 23.3
       2003 100 29.4 28.9
       2008 100 28.3 37.3
Kenya
       1989 100 29.1 18.4
       1993 100 34.8 26.4
       1998 100 27.0 37.5
       2003 100 23.8 45.4
       2008/9 100 18.3 54.8
Madagascar
       1992 100 27.5 31.3
       1997 100 24.7 48.5
       2003/4 100 18.6 55.7
       2008/9 100 20.5 61.3
Malawi
       1992 100 29.7 20.3
        2000 100 10.3 62.8
        2004 100 7.1 64.1
        2010 100 5.9 61.1
Tanzania
        1992 100 51.5 6.1
        1996 100 41.4 33.8
        1999 100 31.4 37.3
        2004 100 29.5 41.5
        2010 100 24.5 38.7
Zimbabwe
        1988 100 85.9 0.8
        1994 100 78.4 7.6
        1999 100 70.4 16.1
        2005/6 100 73.6 17.0
Notes: Calculations based on information in DHS datasets and final reports.
CPR is modern contraceptive prevalence rates.
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Table 3 Multivariate logistic regression analysis of the determinants (odds ratios) for the 
use and non-use of injectables
Variables Ghana Kenya Malawi Madagascar Tanzania Zimbabwe
Place of residence           
  Rural 1:00 1.00 1.00** 1.00 1.00*** 1.00
  Urban 1.18 1.12 1.55 0.85 2.84 0.97
Education
  None 1.00 1.00*** 1.00 1.00*** 1.00 1.00
  Primary 1.21 3.56 1.05 2.29 1.61 0.91
  Secondary/+ 1.04 4.12 1.47 2.64 1.45 1.11
Husband’s attitude to family planning
  Negative 1.00** 1.00*** 1.00*** 1.00*** 1.00*** 1.00***
  Positive 3.82 3.19 6.55 26.32 3.65 3.16
Age
  15-19 1.00* 1.00*** 1.00*** 1.00 1.00* 1.00
  20-24 3.77 1.41 1.51 1.15 1.92 1.23
  25-29 4.04 1.52 1.14 1.32 1.49 1.70
  30-34 3.58 1.22 0.65 1.20 0.93 1.88
  35-39 2.49 0.93 0.43 1.18 0.88 1.63
  40-44 2.53 0.88 0.35 1.11 1.51 1.15
  45-49 1.22 0.35 0.30 0.72 0.53 0.93
No. of living children
  0-1 1.00*** 1.00*** 1.00*** 1.00*** 1.00*** 1.00***
  2 2.63 1.93 2.27 2.18 2.44 1.62
  3 2.63 2.43 3.62 1.94 1.72 3.19
  4 2.83 2.68 4.75 2.27 2.80 3.34
  5+ 2.96 2.24 7.92 2.59 4.04 4.63
Constant -5.951 
(0.990)
-4.650 
(0.315)
-4.609 
(0.172)
-6.278   
(0.67)
-5.229 
(0.518)
-4.688 
(0.427)
 Notes: Asterisks (*) denote the level of statistical significance: * (p<0.05), ** (p<0.01), *** 
(p<0.001).  Analysis is based on data from 2003 Ghana DHS, 2003 Kenya DHS, 2003/4 Madagascar 
DHS, 2004/5 Malawi DHS, 2004 Tanzania DHS and 2005/6 Zimbabwe DHS.
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B. Socio-demographic determinants 
Adjusted odds ratios from a set of mul-
tivariate regression models for selected 
determinants of use or non-use of 
injectables are presented in Table 3. 
They show that only two variables 
(number of living children and hus-
band’s attitude to family planning) were 
statistically significant correlates of 
injectable use in all countries in the 
table. Women who have two or more 
children were much more likely to use 
injectables than women with one or no 
children. In most countries, the odds 
ratios for using injectables were highest 
for women with 5+ living children. The 
odds ratio was about 8:1 in Malawi, 
about 5:1 in Zimbabwe and about 4: 1 
in Tanzania. 
Similarly, wives were much more 
likely to be using injectables if their hus-
bands had positive attitudes to family 
planning. The odds ratio was at 26:1 in 
Madagascar and about 7:1 in Malawi. In 
the other four countries, they are about 
3 or 4 to 1. The age of women at the 
time of interview was a statistically sig-
nificant predictor of injectables use in 
four of the six countries (Kenya, 
Malawi, Ghana and Tanzania). In most 
of these countries, use of injectables 
peaked among women in ages 20-29. 
Women’s level of education and place 
of residence were statistically significant 
only in Malawi and Tanzania. In each of 
these countries, the prevalence of 
injectables was higher in urban areas 
and increased with women’s level of 
education. It is interesting that in Zim-
babwe where the pill is the dominant 
method, only the husband’s attitude to 
family planning and number of living 
children are statistically significant as 
predictors of injectable use.T
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Although the analysis of determi-
nants offer useful insights into the back-
ground factors that are associated with 
the use of injectables in these countries, 
it does not really tell us much about 
why the rate of increase is very rapid in 
many African countries. It therefore 
seems logical for us to look at the 
hypotheses that may offer insights. 
C. The secret use hypothesis
As already indicated, it has been 
hypothesized that one attraction of 
injectable contraceptives is that women 
could hide their use from non-coopera-
tive spouses or other household mem-
bers. The question is whether we have 
evidence that supports the hypothesis. 
To investigate this question, we ana-
lyzed data from matched couple’s files 
in the latest DHS in each country. We 
wanted to see the extent of agreement 
or disagreement between spouses in 
their reported current contraceptive 
methods. The results are presented in 
Table 4 and they show that men tend to 
slightly over-report their wives’ use of 
pills – over-reporting by about 20% in 
Ghana and Zimbabwe. The biggest 
divergence in reporting was in injecta-
bles and condoms. The percentage of 
men who reported injectables as cur-
rent contraceptive method is generally 
lower than the percentage of their 
spouses who reported using injectables. 
In Kenya for example, the proportion of 
women who reported pills as their cur-
rent method was about the same as the 
proportion of men who reported the 
method. However, the proportion of 
women who reported injectables 
(which is likely to approximate reality) 
was 59% higher than the proportion of 
men in the couples’ file reporting the 
method. The proportion was 36% 
higher in Malawi and 25% higher in 
Ghana. In terms of agreement in the 
reported use of the pills, the results 
suggest that men generally tend to 
overestimate the proportion of their 
spouses using the pill. Similarly, women 
tend to under-estimate the proportion 
of their spouses using condoms.
Although a lack of correspondence 
in couple’s reported current method of 
contraception could be interpreted as 
evidence that some men do not know 
that their spouses are using injectables, 
it should be realized that this approach 
to testing the secrecy hypothesis may 
be flawed especially in settings where 
polygyny or concurrent partnership is 
common. One of the ways to check 
whether wives were secretly using 
injectables is to look at the proportion 
of women using injectables but who 
were reported by their husbands as not 
using any method The results (not pre-
sented) shows that in Ghana, 25% of 
women who reported injectables as 
their current method were reported as 
using no method by their spouses. That 
seems to be a better indicator of secret 
use. The percentage of women who 
seem to use the injectables secretly was 
similar in Malawi (27%), but was lower 
in Kenya (15%) and in Zimbabwe (5%). 
In Zimbabwe, 30% of men whose 
spouses were using injectables 
reported them as using the pill. Most 
husbands know that their wives were 
using some contraceptive method, even 
if they don’t know which one. 
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D. The convenience hypothesis
Apart from offering privacy conven-
ience is another major advantage of 
injectable contraceptives. Certain 
aspects of this convenience advantage 
may work in the interest of rural 
women and those with low levels of 
education. For instance, it is likely that 
the increase in the use of injectables will 
be more rapid in rural areas where 
service delivery points may be sparse 
and difficult to access, where traditional 
attitudes to the use of modern family 
planning methods may prevail, where 
maintaining daily regimen of the pills 
may be less appealing, and where atti-
tudes of husbands to the use of family 
planning methods may be more con-
servative. If this is true, we would 
expect the uptake of the injectables to 
be more rapid in rural than urban areas. 
However, people in rural areas tend to 
be more traditional and superstitious in 
outlook than those in urban areas. 
Thus, fear of side effects may actually 
scare users away from continuing to use 
injectable methods. Since service provi-
sion in rural areas may be less reliable 
than in urban areas, it is often difficult to 
separate lack of access from lack of 
interest.
Table 5 Rural-urban trends in the percentage of married women using injectable 
contraceptives 
Survey 1
(%)
Survey 2
(%)
Survey 3
(%)
Latest 
(%)
Ratio Latest/First 
survey
Ghana
   Rural 0.2 1.4 2.8 6.3 31.0
   Urban 0.3 2.0 3.8 6.2 21.0
 Kenya
   Rural 3.4 7.4 11.6 21.0 6.2
   Urban 2.8 6.2 12.6 23.5 8.4
Madagascar
   Rural 1.4 3.4 9.7 17.9 12.8
   Urban 2.6 8.3 11.9 18.1 7.0
Malawi
   Rural 1.4 15.3 17.1 25.5 18.2
   Urban 2.2 22.9 22.5 27.2 12.4
Tanzania
   Rural 0.2 3.1 6.9 9.4 47.0
   Urban 1.2 9.5 12.6 14.3 11.9
Zimbabwe
   Rural 0.2 3.0 8.3 9.2 46.0
   Urban 0.5 3.6 7.6 11.2 22.4
http://aps.journals.ac.za
 African Population Studies Vol  25, 2 (Dec 2011)
600
To examine the rural convenience 
hypothesis, we look at rural and urban 
distribution of users of injectables and 
the trend (see Table 5). The results 
show that in almost every country in 
this study, the use of injectable contra-
ceptives increased over time in both 
rural and urban areas. However, with 
the exception of Kenya where the prev-
alence of injectable in the first survey 
was higher in rural than in urban area, 
the prevalence of injectables increased 
much faster in rural areas than in urban 
areas. The rural area with the fastest 
increase in the prevalence of injectables 
was in Tanzania: the ratio of prevalence 
in the latest to first DHS was 47:1, 
while it was 12:1 in urban areas. Simi-
larly in Zimbabwe, latest to first ratio in 
the prevalence of injectables was 46:1 
in rural areas compared to 22:1 in 
urban areas. In Ghana, the prevalence 
of injectables in the latest DHS was 31 
times that in the first survey in rural 
areas and 21 times in urban areas. In 
Malawi, rural prevalence of injectable 
grew by a factor of 18, but by 12 in 
urban areas. In Madagascar, the corre-
sponding numbers are 13 in rural areas 
and 7 in urban areas.
In sum, the results show a narrow-
ing of urban-rural gap over time in a 
majority of the countries in this analysis. 
The conclusion from Table 5 is that 
uptake of injectables has grown much 
faster in rural areas. Given that urban 
areas have higher density of health facil-
ities and health care providers, and 
more educated and well-to-do people, 
and are hence more resourced to pro-
vide easier access to injectables, its 
faster growth in adoption in rural areas 
suggest that the convenience hypothe-
sis may indeed be true and perhaps 
indirectly the secrecy hypothesis has 
some support.
What will the future look like for 
injectables?
Although future pattern of contracep-
tive use may not be easy to predict, a 
simple way to anticipate trends in 
demand for contraceptive methods is 
to look at the preferred methods for 
future use among women who are cur-
rent non-users of contraception but 
who intend to use a method in the 
Table 6 Preferred methods for future use among women who are currently not using any 
methods but intend to use in future (column %) 
Method Ghana Kenya Malawi Tanzania Zimbabwe
Pill 15.4 13.0 17.9 25.9 56.8
IUD 3.4 1.4 1.4 1.9 1.6
Injection 42.5 46.6 59.2 45.6 26.5
Implants 11.1 7.2 1.4 3.1 1.8
Condom 2.9 1.3 4.9 2.7 1.2
Fem Steriliz 3.6 7.9 9.9 8.1 4.7
Unsure 12.5 15.3 1.6 5.2 2.7
Total* 100.0 100.0 100.0 100.0 100.0
* Total will not add to 100 because some minor methods are omitted from the table.
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future. This is the focus of Table 6, and 
it shows that the pill would continue to 
dominate the contraceptive method 
mix in Zimbabwe in the near future. 
However, for the other countries in the 
table, users of injectables and implants 
would dominate the contraceptive 
scenes. For example in Kenya, the pro-
portion of non-users of contraception 
who intend to use the injectables and 
implants (54%) is four times the pro-
portion intending to use the pill (13%). 
In Ghana, the proportion of potential 
users of injectables and implants is 
three and a half times the proportion 
intending to use the pill, and in Malawi, 
it is more than three times. If you put 
this side by side with with the US, the 
picture is quite interesting. In spite of 
the fact that the method is reversible, 
highly effective and convenient, it 
seems that their acceptance rate in the 
US remains very low (Tanfer et al., 
2000). Only 3% of women at risk of 
unintended pregnancy were using the 
injectables in 1995.
Discussions
So far in this paper, we have shown that 
injectable contraceptive methods are 
fast becoming the method of choice 
among married women in several sub-
Saharan African countries. The fastest 
increases are in Zimbabwe with 33-fold 
increase in about 15 years, Tanzania 
with 27-fold increase in 18 years, and 
Malawi with seventeen-fold increase 
also in 18 years. There are many pro-
grammatic implications of the rising 
prevalence of injectables in sub-Saharan 
Africa. One is how to pay the cost of 
purchasing contraceptive commodities 
and supplies, which are increasing every 
year. Injectables are not the least 
expensive of longer-acting reversible 
methods. Available data from USAID 
Office of Population indicate that one 
couple year of protection (CYP) for 
DMPA costs about $4.32 without 
counting the cost of service delivery. 
This is 32% higher than the cost of one 
CYP for pills and 9 times the cost of 
one CYP of intrauterine device (IUD). 
More and more of these injectables 
need to be procured every year. 
Between 2003 and 2005, shipments of 
doses of injectables by the United 
Nations Population Fund, USAID and 
the International Planned Parenthood 
Federation – the three largest donors 
of contraceptive commodities – more 
than doubled from 23 to 48 million 
doses per year (Lande and Richey, 
2006:4). This demand is projected to 
increase to 150 million doses per year 
by 2010. 
Even if there is contraceptive secu-
rity, there is the second challenge of 
making it available to clients even in the 
remote villages of Africa. The cost issue 
is especially important because a large 
percentage of the commodity that 
underpins this rising prevalence is heav-
ily subsidized by donors and is made 
available free to almost all users, with 
limited contributions from host-country 
government even for commodities in 
public facilities. The extent to which 
injectables will continue to be popular 
without this donor support is unknown. 
However in Malawi, there was an expe-
rience that might be illustrative: an 
attempt to introduce user-pay system 
by one of the leading private sector 
providers services – Banja La Msogolo –
led to a drop in the number of clients 
from about 175,000 in 1999 to about 
94,000 in 2001. When subsidized serv-
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ices were re-instated in 2002, the 
number of clients in its clinics increased 
to about 136,000 in 2002 and 350,000 
in 2003 (Solo et al, 2005).
Finally, although the rising preva-
lence of injectable contraceptives has 
helped many families avoid unintended 
pregnancies, it is also important to be 
cognizant of the fact that this increase in 
happening in some countries where 
HIV prevalence is also high. Therefore, 
it is important for family planning serv-
ice providers to remind women that 
injectable contraceptives, like all non-
barrier methods, do not protect against 
sexually transmitted diseases, including 
HIV. WHO encourages women and 
men to use dual protection approaches 
whenever there is any possibility of 
exposure to STI and HIV (WHO, 2004, 
2005). 
Summary and conclusion
In this paper, data from selected coun-
tries in sub-Saharan Africa have been 
analyzed to illustrate the rising popular-
ity of injectable contraceptives. The 
results of the analysis show clearly that 
injectables have become the leading 
modern contraceptive method in sev-
eral countries in sub-Saharan Africa. 
Their relative size in the contraceptive 
method mix is increasing rapidly in 
every country in this study and they are 
popular in both urban and rural areas in 
the region. However, the rate of 
increase in the prevalence of injectables 
tends to be higher in rural than urban 
areas in almost all countries here, thus 
suggesting that convenience may be 
part of the reason for the popularity. 
There is also some support for the 
secrecy factor, although most men are 
aware that their spouses were using 
some form of contraception even if 
they do not know which one it is. Look-
ing at future trends in the countries 
studied, there is evidence that the pop-
ularity of injectable will continue to 
increase, all things being equal. The 
implication of this rising popularity of 
injectables is discussed in the light of 
cost and sustainability of family planning 
program, particularly in resource-poor 
settings, and in the context of HIV/AIDS 
and of possible long-term effects.
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